These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 18165109)

  • 1. The causes of the Charcot syndrome.
    Jeffcoate W
    Clin Podiatr Med Surg; 2008 Jan; 25(1):29-42, vi. PubMed ID: 18165109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of polymorphisms in OPG, RANKL and RANK as potential markers for Charcot arthropathy development.
    Bruhn-Olszewska B; Korzon-Burakowska A; Węgrzyn G; Jakóbkiewicz-Banecka J
    Sci Rep; 2017 Mar; 7(1):501. PubMed ID: 28356555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.
    Panizo S; Cardus A; Encinas M; Parisi E; Valcheva P; López-Ongil S; Coll B; Fernandez E; Valdivielso JM
    Circ Res; 2009 May; 104(9):1041-8. PubMed ID: 19325147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease.
    Liu W; Feng W; Wang F; Li W; Gao C; Zhou B; Ma M
    Exp Mol Pathol; 2008 Jun; 84(3):213-7. PubMed ID: 18417124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased osteoclastic activity in acute Charcot's osteoarthopathy: the role of receptor activator of nuclear factor-kappa B ligand.
    Pandolfi F; Pitocco D; Cianci R; Mancini L; Ghirlanda G
    Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):69-70. PubMed ID: 20184092
    [No Abstract]   [Full Text] [Related]  

  • 6. [Genomic approaches to bone and joint diseases. Mutations of RANK, OPG and RANKL genes found in humans].
    Kobayashi Y; Takahashi N
    Clin Calcium; 2008 Feb; 18(2):202-9. PubMed ID: 18245890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes.
    Jeffcoate WJ; Game F; Cavanagh PR
    Lancet; 2005 Dec; 366(9502):2058-61. PubMed ID: 16338454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Osteoprotegerin mRNA/receptor activator of NF-kappaB ligand mRNA expressions in bone tissues of glucocorticoid-induced osteonecrosis of the femoral head].
    Wang J; Wang K; Shi Z; Zhang M
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Oct; 22(10):1161-4. PubMed ID: 18979868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
    Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
    J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function.
    McGonigle JS; Giachelli CM; Scatena M
    Angiogenesis; 2009; 12(1):35-46. PubMed ID: 19105036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormalities of vasomotor regulation in the pathogenesis of the acute charcot foot of diabetes mellitus.
    Jeffcoate WJ
    Int J Low Extrem Wounds; 2005 Sep; 4(3):133-7. PubMed ID: 16100093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Regulation of receptor activator of nuclear factor kappaB ligand and osteoprotegerin expression by prostaglandin E2 in osteoblastic-like cells].
    Wang BL; Zheng F; Qiu MC
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1992-6. PubMed ID: 19062743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OPG, RANK and RANK ligand expression in thyroid lesions.
    Heymann MF; Riet A; Le Goff B; Battaglia S; Paineau J; Heymann D
    Regul Pept; 2008 Jun; 148(1-3):46-53. PubMed ID: 18367263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential profile of the OPG/RANKL/RANK-system in degenerative aortic native and bioprosthetic valves.
    Steinmetz M; Skowasch D; Wernert N; Welsch U; Preusse CJ; Welz A; Nickenig G; Bauriedel G
    J Heart Valve Dis; 2008 Mar; 17(2):187-93. PubMed ID: 18512489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?
    Spelling P; Bonfá E; Caparbo VF; Pereira RM
    Scand J Rheumatol; 2008; 37(6):439-44. PubMed ID: 18802807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Charcot neuro-osteoarthropathy.
    Jeffcoate WJ
    Diabetes Metab Res Rev; 2008; 24 Suppl 1():S62-5. PubMed ID: 18393327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
    Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
    Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
    Schubert A; Schulz H; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
    Bai YD; Yang FS; Xuan K; Bai YX; Wu BL
    Med Hypotheses; 2008 Aug; 71(2):256-8. PubMed ID: 18445511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.